Search
Search
About
Log in
Join
Experiences with
Acute leukaemia
Posts
Communities
2,770 public posts
Filter results
Imbruvica-related issues: Qs + comments
The following are questions and comments I'll be asking my oncologist when I see him tomorrow. I believe at least some of them might be relevant to what some among us are experiencing and research some of us are engaging in. Clearly, none of the comments here are meant to be authoritative nor intended
The following are questions and comments I'll be asking my oncologist when I see him tomorrow. I believe at least some of them might be relevant to what some among us are experiencing and research some of us are engaging in. Clearly, none of the comments here are meant to be authoritative nor intended
Pogee
in
CLL Support
4 years ago
FCR
I’ll avoid FCR at all. Dangerous and tricky. Increase the probability of AL occurrence as well as second neoplasm and Richter transformation in the long run. You have to be "fit patient” to receive FCR, IGHV mutated and without tp53 mutation or 17p deletion. Find a responsible doctor with a robust experience
I’ll avoid FCR at all. Dangerous and tricky. Increase the probability of AL occurrence as well as second neoplasm and Richter transformation in the long run. You have to be "fit patient” to receive FCR, IGHV mutated and without tp53 mutation or 17p deletion. Find a responsible doctor with a robust experience
Rccfrc00
in
CLL Support
4 years ago
Sweet's syndrome during induction chemotherapy for acute myeloid leukemia – case report and mini review.
In 15-20% of cases, Sweet's syndrome (SS) develops secondary to cancer, the blood cancer,
acute
myeloid
leukaemia
(AML), being the commonest. Out of the total number of malignancy-associated cases, 85% have blood cancer.
In 15-20% of cases, Sweet's syndrome (SS) develops secondary to cancer, the blood cancer,
acute
myeloid
leukaemia
(AML), being the commonest. Out of the total number of malignancy-associated cases, 85% have blood cancer.
Shell567
Sweet's Syndrome UK
in
Sweet's Syndrome UK
4 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
flair ..fcr
hi all i have had cll from 2012 i have been on w&w my question is i have signed up for the flair trail Manchester Christie i got phone call this week saying i was randomized for FCR my age is 57yrs i have no tp53 or any other abnormal readings and i dont know what my mutations are etc mutated or unmutated
hi all i have had cll from 2012 i have been on w&w my question is i have signed up for the flair trail Manchester Christie i got phone call this week saying i was randomized for FCR my age is 57yrs i have no tp53 or any other abnormal readings and i dont know what my mutations are etc mutated or unmutated
kel555
in
CLL Support
4 years ago
Documented remission without drugs
I've just come across an article on a remarkable, well-documented, case of a younger man with CLL who, over time, achieved complete remission without drugs. Here's the link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4739749/ * I hasten to add that this is but a single case, and I'm not recommending
I've just come across an article on a remarkable, well-documented, case of a younger man with CLL who, over time, achieved complete remission without drugs. Here's the link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4739749/ * I hasten to add that this is but a single case, and I'm not recommending
Pogee
in
CLL Support
4 years ago
Can Venetoclax/Obinituzimab reduce the risk of additional somatic mutations? - Not necessarily. The BTK inhibitors are excellent at....
Below is a repost from CLLSLL@groups.io ( permission granted by Dr. Furman) - I believe this hypothesis may be tested in a proposed clinical trial Dr. Furman has mentioned in the past- Len - Can Venetoclax/Obinituzimab reduce the risk of additional somatic mutations? From: ------ Date: Thu, 23 Jul
Below is a repost from CLLSLL@groups.io ( permission granted by Dr. Furman) - I believe this hypothesis may be tested in a proposed clinical trial Dr. Furman has mentioned in the past- Len - Can Venetoclax/Obinituzimab reduce the risk of additional somatic mutations? From: ------ Date: Thu, 23 Jul
lankisterguy
Volunteer
in
CLL Support
4 years ago
Resistance-Associated Mutations in CLL Patients Treated With Novel Agents
This is slightly complex but good overview of the acquired resistance mechanisms to novel agents. In 80% of patients with ibrutinib failure, acquired mutations in BTK and PLCG2 genes were detected. No common resistance-associated mutations or deregulated signaling pathways have been reported in idelalisib
This is slightly complex but good overview of the acquired resistance mechanisms to novel agents. In 80% of patients with ibrutinib failure, acquired mutations in BTK and PLCG2 genes were detected. No common resistance-associated mutations or deregulated signaling pathways have been reported in idelalisib
Jm954
Administrator
in
CLL Support
4 years ago
Richter transformation after quitting ibrutinib: a diagnostic error
Hi all. The topic of the connection between Ibrutinib and the Richter transformation is getting very interesting. In the group that I have on Facebook every day people are entering that once Ibrutinib left a few days for an operation or biopsy for another movement, Richter was diagnosed. Then the Pet
Hi all. The topic of the connection between Ibrutinib and the Richter transformation is getting very interesting. In the group that I have on Facebook every day people are entering that once Ibrutinib left a few days for an operation or biopsy for another movement, Richter was diagnosed. Then the Pet
Priss69
in
CLL Support
4 years ago
CSIRO uses lab-grown ‘lungs’ to fight respiratory viruses
Researchers at Australia's national science agency, CSIRO, found that lab-grown cells from the upper layer of the airway to the lungs – the human bronchial epithelium – reliably mimic a live person's airway's response to viruses. CSIRO Research Scientist Dr Elizabeth Pharo is the lead author on the findings
Researchers at Australia's national science agency, CSIRO, found that lab-grown cells from the upper layer of the airway to the lungs – the human bronchial epithelium – reliably mimic a live person's airway's response to viruses. CSIRO Research Scientist Dr Elizabeth Pharo is the lead author on the findings
2greys
in
Lung Conditions Community Forum
4 years ago
Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies
Abstract This review reflects the presentations and discussion at the 14th post‐ASH International Workshop on Chronic Myeloproliferative Malignancies, which took place on the 10th‐11th December 2019, immediately after the 61st American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. Rather
Abstract This review reflects the presentations and discussion at the 14th post‐ASH International Workshop on Chronic Myeloproliferative Malignancies, which took place on the 10th‐11th December 2019, immediately after the 61st American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. Rather
Manouche
in
MPN Voice
4 years ago
CLL Society Dr. Koffman's ASCO 2020 "Top 12" Picks #s 12, 11, 10
Dr. Koffman’s ASCO 2020 “Top 12” Picks The 2020 Annual Meeting of the American Society of Clinical Oncology (ASCO) was held virtually in May. While ASCO remains more focused on the latest research in solid tumors, there were several worthwhile abstracts related to CLL. Dr. Koffman takes us through his
Dr. Koffman’s ASCO 2020 “Top 12” Picks The 2020 Annual Meeting of the American Society of Clinical Oncology (ASCO) was held virtually in May. While ASCO remains more focused on the latest research in solid tumors, there were several worthwhile abstracts related to CLL. Dr. Koffman takes us through his
bkoffman
CLL CURE Hero
in
CLL Support
4 years ago
CLL/SLL Roundtable: Updates on Patient Management (including low dose radiation treatment for early stage SLL)
Joshua Brody, MD, Richard Bakst, MD, and Amir Steinberg, MD, of the Icahn School of Medicine at Mount Sinai, New York City, discuss updates on the management of patients with small lymphocytic lymphoma (SLL) and chronic lymphocytic leukemia (CLL). The conversation includes discussion on radiation therapy
Joshua Brody, MD, Richard Bakst, MD, and Amir Steinberg, MD, of the Icahn School of Medicine at Mount Sinai, New York City, discuss updates on the management of patients with small lymphocytic lymphoma (SLL) and chronic lymphocytic leukemia (CLL). The conversation includes discussion on radiation therapy
AussieNeil
Partner
in
CLL Support
4 years ago
W&W CLL Patient in Need of Advice
CLL patient for 4 years with 22 wbc and on w&w I visited my Oncologist last Tuesday and explained that I am experiencing a continuous high level of body pain hoping that I would receive something other than take some Advil. Not sure if they understand that this is a daily pain and I cannot be expected
CLL patient for 4 years with 22 wbc and on w&w I visited my Oncologist last Tuesday and explained that I am experiencing a continuous high level of body pain hoping that I would receive something other than take some Advil. Not sure if they understand that this is a daily pain and I cannot be expected
Hidden
in
CLL Support
4 years ago
Bendamustine with rituximab
my husband was diagnosed with CLL and will be starting on the above agents over the next 6 months. Anyone has experienced the same treatment before?
my husband was diagnosed with CLL and will be starting on the above agents over the next 6 months. Anyone has experienced the same treatment before?
gohmei
in
CLL Support
4 years ago
Triplet Regimen Shows Promise in CLL -Zanubrutinib, obinutuzumab, & venetoclax combo achieves rapid undetectable MRD -MedPageToday -07/07/20
Treatment triple-header news from the MedPage Today. From the article: [i]At the American Society of Clinical Oncology virtual meeting, initial findings from a phase II study were reported on minimum residual disease (MRD)-driven, time-limited therapy with a regimen known as BOVen (zanubrutinib, obinutuzumab
Treatment triple-header news from the MedPage Today. From the article: [i]At the American Society of Clinical Oncology virtual meeting, initial findings from a phase II study were reported on minimum residual disease (MRD)-driven, time-limited therapy with a regimen known as BOVen (zanubrutinib, obinutuzumab
cujoe
in
CLL Support
4 years ago
Videos now available - Webinar talks and Q&A sessions - leukaemia and COVID - 19
These webinars on
acute
leukaemia
and chronic lymphocytic leukaemia (CLL) can now be found on our YouTube > In the videos leading consultants are joined by patients as they discuss and answer questions about how COVID-19 is affecting
leukaemia
patients.
These webinars on
acute
leukaemia
and chronic lymphocytic leukaemia (CLL) can now be found on our YouTube > In the videos leading consultants are joined by patients as they discuss and answer questions about how COVID-19 is affecting
leukaemia
patients.
HAIRBEAR_UK
in
Leukaemia Support
4 years ago
A JEDI WARRIOR's TALE
Post by MPN-MATE Admin » Sun Jun 21, 2020 10:52 am Morning everyone... :-) I am feeling quite chuffed and privileged today as we have just had someone that has always inspired my own MPN journey, (join us here at MATES), by penning his arduous account of what is was like to go through the whole process
Post by MPN-MATE Admin » Sun Jun 21, 2020 10:52 am Morning everyone... :-) I am feeling quite chuffed and privileged today as we have just had someone that has always inspired my own MPN journey, (join us here at MATES), by penning his arduous account of what is was like to go through the whole process
socrates_8
in
MPN Voice
4 years ago
Webinar - Coronavirus and acute leukaemia
Dr Patel will discuss the potential changes to your care as a result of the coronavirus outbreak as well as providing advice on living with
acute
leukaemia
at this time.
Weds 8th April 10.15am
Register here https://zoom.us/webinar/register/WN_KeFZJqvmSZ6UEkVptgaaQw
Dr Patel will discuss the potential changes to your care as a result of the coronavirus outbreak as well as providing advice on living with
acute
leukaemia
at this time.
Weds 8th April 10.15am
Register here https://zoom.us/webinar/register/WN_KeFZJqvmSZ6UEkVptgaaQw
HAIRBEAR_UK
in
Leukaemia Support
4 years ago
Normal CBC abnormal flow test
I had two months of abnormal CB results, and the flow study also abnormal. I was diagnosed with possible CLL. I then had a CBC done yesterday after three months and everything in the CBC is normal. Do I now not have a Blood cancer? Is it a miracle or does this happen sometimes? I have had no treatment
I had two months of abnormal CB results, and the flow study also abnormal. I was diagnosed with possible CLL. I then had a CBC done yesterday after three months and everything in the CBC is normal. Do I now not have a Blood cancer? Is it a miracle or does this happen sometimes? I have had no treatment
gustave
in
CLL Support
4 years ago
Fatigue with CLL
Hello I was diagnosed cll on January 2019 cll stage 0, my wbc was 30, on June 2020 is 49 no symptoms except my gamma globulin is slightly lower than normal. I am still on w/w, but i feel all time tired and I cannot work on morning, I start only at 14h. Also I am anxious, I think all time about my cll
Hello I was diagnosed cll on January 2019 cll stage 0, my wbc was 30, on June 2020 is 49 no symptoms except my gamma globulin is slightly lower than normal. I am still on w/w, but i feel all time tired and I cannot work on morning, I start only at 14h. Also I am anxious, I think all time about my cll
Hicham
in
CLL Support
4 years ago
1
...
52
53
54
...
100
Next page
10
20
30
40
50
60
70
80
90
100
Filter results
Clear filters
Posted in
All communities
CLL Support
1634 results
MPN Voice
795 results
Leukaemia Support
171 results
View top 10 communities
Sort by
Most Relevant
Newest